Background: Diagnosis of prostate cancer is certified by histology true prostate\nbiopsies. The aim of our study was to evaluate our prostate biopsy method.\nMaterial and Methods: It was a prospective study including patients\nunderwent prostate biopsy. Inclusion criteria were prostate specific antigen\n(PSA) level up to 4ng/ml and/or abnormal prostate at digital rectal examination.\nPatients who had risk factors of bleeding have been excluded of the\nstudy. The preparation before biopsy included antibioprophylaxy (Ciprofloxacine-\nTinidazole) and rectal hypertonic cleaning (Normacol*). Twelve cores\nhave been taken in each prostate by transrectal digital-guided way, using Biopty\nGun 18 Gauge. Local anesthesia has been done previously by intrarectal\napplication of 20 ml of gel of Lidoca�¯ne. Two other cores were taken into each\nabnormal area at rectal examination. The follow-up have been done during\ntwelve weeks. Results: Eighty patients of 65 years of age were included. Nine\npatients had familial history of prostate cancer. PSA levels ranged from 5 to\n6400 ng/ml with a median of 26.77 ng/ml �± 11.2. Complications occurred in\n11.25% of patients, principally infectious complications which caused death of\none patient by septicemia. The rate of cancer detection was 20%. Prostate abnormality\nat digital rectal examination and the presence of familial history of\nprostate cancer were not predictive factors of the presence of cancer on cores.\nConclusion: Our prostate biopsy method is limited by the lack of ultrasonographic\nguidance and is at important risk of infectious complications.
Loading....